ArticleBioinformation2026
Impact of nocturnal oxygen supplementation on sleep quality and daytime fatigue among interstitial lung disease (ILD) patients.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A collection of more than 300 conditions known as interstitial lung diseases (ILDs) limit oxygen delivery by generating persistent inflammation and irreversible lung tissue scarring, or fibrosis. There is progressive impairment of gas exchange and are frequently complicate by nocturnal hypoxemia. It remains under-recognized despite its significant impact on sleep quality and daytime functioning. Therefore, it is of interest to report the effect of nocturnal oxygen supplementation on sleep quality and daytime fatigue in patients with interstitial lung disease. Total included 228 participants were randomized into two groups: nocturnal oxygen supplementation (n=114) and placebo (sham oxygen) (n=114). Sleep parameters were assessed using overnight monitoring. The Pittsburgh Sleep Quality Index (PSQI), while daytime fatigue and sleepiness were evaluated using validated scales. Statistical analysis was performed using appropriate inferential tests, with p < 0.05 considered significant. Nocturnal oxygen supplementation significantly improves both objective and subjective sleep parameters while reducing daytime fatigue in ILD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.